Induction of Apoptosis and Cell Cycle Arrest by Imexon in Human Pancreatic Cancer Cell Lines
Authors:
- 1 January 2005
- journal article
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 36 (1) , 015-028
Abstract
Imexon is an aziridine-containing small molecule currently in Phase I clinical trials. This agent has been shown to bind to thiols and increase intracellular oxidants, inducing apoptosis in hematologic cancer cells. Pancreatic cancers are known to be sensitive to oxidation, suggesting this disease may be an appropriate target for this agent. The current report examines the activity of imexon in pancreatic cells. Imexon induced concentration-dependent and time-dependent apoptosis in a panel of six human pancreatic carcinoma cell (PCC) lines. The mean IC50 (SD) for growth inhibition by the SRB assay was 200 (101) µM for a 48 h exposure with a range of 64–358 µM. Cell killing was schedule-dependent, favoring exposure times ≥48 h. Imexon-treated MiaPaCa-2 cells underwent non-lethal growth arrest following exposure to concentrations ≤200 µM for 48 h. When concentrations were increased to 300 µM for ≥48 h, the MiaPaCa-2 cells arrested in G2 phase and activated caspases 3, 8, and 9 were detected. After a 72 h exposure to the IC80 concentration of imexon, cells exhibited a loss of mitochondrial membrane potential detected by CMXRos staining. However, there was no loss of reduced cellular thiols unless very high concentrations of ≥400 µM were used. In contrast, reactive oxygen species (ROS) were elevated in a dose-dependent fashion, starting at very low imexon concentrations. Imexon also significantly inhibited MiaPaCa-2 tumor growth in SCID mice at 100 mg/kg/d for 9 d. The tumor growth inhibition (% T/C) was 27% of control, and the tumor growth delay was 21 d, indicating an active agent by NCI standards. The levels of imexon that are cytotoxic in human PCC’s are achievable based on the preliminary results of the ongoing Phase I trial. Imexon appears to be active against PCCs in vitro and has an entirely novel mechanism of action involving G2 arrest, accumulation of ROS, and the induction of apoptosis.Keywords
This publication has 44 references indexed in Scilit:
- Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2003
- Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cellsAnti-Cancer Drugs, 2002
- Detection of Caspase Activation In Situ by Fluorochrome-Labeled Caspase InhibitorsBioTechniques, 2001
- Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinomaCancer, 2001
- Definitive Results of a Phase II Trial of Cisplatin, Epirubicin, Continuous-Infusion Fluorouracil, and Gemcitabine in Stage IV Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2001
- Combined Radiation and 9‐Nitrocamptothecin (Rubitecan) in the Treatment of Locally Advanced Pancreatic CancerAnnals of the New York Academy of Sciences, 2000
- Superoxide generation in v-Ha-ras-transduced human keratinocyte HaCaT cellsMolecular Carcinogenesis, 1999
- Chloromethyl-X-rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosisCytometry, 1996
- Sensitivity of Multiple Myeloma to Imexon in the Human Tumor Cloning AssayJNCI: Journal of the National Cancer Institute, 1994
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI: Journal of the National Cancer Institute, 1990